TAI · 6446.TW
PharmaEssentia Corporation
NT$1,160.00NT$0.00 (0.0%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
Loading market information…
TWO · 6576.TWO · TWD
Stock price, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Foresee Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.96% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Foresee Pharmaceuticals Co., Ltd.’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of -NT$0.89. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Foresee Pharmaceuticals Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Foresee is a Taiwan and US-based biopharmaceutical company focused on two key areas: its unique Stabilized Injectable Formulation (SIF) long-acting injectable technology with derived drug products for specialty markets, and its transformative preclinical and clinical first-in-class New Chemical Entity (NCE) programs targeting rare and severe disease areas with high unmet needs. Its product portfolio includes late and early-stage programs, with its lead product CAMCEVI® used for the treatment of advanced prostate cancer.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 | Feb 19, 2025 | -NT$1.45-5.33% vs estimate | NT$147.00M0.0% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | -NT$2.25-34.73% vs estimate | NT$80.00M-28.57% vs estimate |
|---|
| Q2 2024 | Aug 14, 2024 | -NT$1.21+13.57% vs estimate | NT$97.21M-0.81% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$1,160.00NT$0.00 (0.0%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
NT$158.50NT$0.00 (0.0%)
Lin BioScience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
NT$39.50NT$0.00 (0.0%)
Pell Bio-Med Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.38% below the high.
NT$57.40-NT$2.60 (-4.33%)
TaiMed Biologics Inc.’s quoted price sits in the lower half of its reported 52-week range, 23.87% below the high.
NT$27.10-NT$0.10 (-0.37%)
Pharmosa Biopharm Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.83% below the high.
NT$5.85-NT$0.09 (-1.52%)
Mercury Biopharmaceutical Corporation’s quoted price sits in the lower half of its reported 52-week range, 52.05% below the high.
